Santarus Inc (SNTS)

Currency in USD
31.96
0.00(0.00%)
Closed·
Showing Santarus historical data. For real-time data please try another search
Day's Range
31.9632.04
52 wk Range
0.0032.04
Key Statistics
Prev. Close
31.96
Open
31.99
Day's Range
31.96-32.04
52 wk Range
0-0
Volume
-
Average Volume (3m)
2.57M
1-Year Change
0%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Santarus Inc News & Analysis

Show more

Santarus Inc Company Profile

Santarus, Inc., a specialty biopharmaceutical company, focuses on acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists. The company offers UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis; and ZEGERID (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders. It also provides GLUMETZA (metformin hydrochloride extended release tablets) and CYCLOSET (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes; and FENOGLIDE (fenofibrate) tablets, which are indicated as an adjunct to diet to reduce high cholesterol. Santarus' product development pipeline includes the investigational drug RUCONEST (recombinant human C1 esterase inhibitor) for the treatment of acute angioedema attacks in patients with hereditary angioedema. It is also developing Rifamycin SV MMX, which is in Phase III clinical testing for the treatment of travelers' diarrhea. In addition, the company has completed a Phase I clinical program with SAN-300, an investigational monoclonal antibody. Santarus, Inc. was founded in 1996 and is headquartered in San Diego, California. As of December 31, 2013, Santarus, Inc. operates as a subsidiary of Salix Pharmaceuticals, Inc.

Employees
290

Earnings

Latest Release
Mar 05, 2019
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SNTS Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.